In recent years, immunotherapy, a treatment that enhances the body’s own immune cancer-fighting response, has been shown to be a very promising treatment option. Immunotherapy has proven effective for treating multiple cancer types, including some types of non-small cell lung cancer (NSCLC). Among these NSCLC patients, currently about 20% respond to the treatment.
Unfortunately, there may be toxicities, or side effects, of immunotherapy, and they are challenging to predict. Because immunotherapy works by taking the brakes off the immune system, every part of the body has the...
By Kylie Buchan RDN, CSO, Savor Health, March 1, 2019
Hydration is one of the most important factors for lung cancer patients. Dehydration can cause you to be lightheaded or dizzy, but also make treatment-related side effects, like nausea, dry mouth, and constipation, much worse.1 Research has also shown that when cancer patients are fully hydrated, they have fewer complications and better quality of life compared with those who are dehydrated.2 However, for cancer patients and caregivers, it can be difficult to know what to drink and how much.
As we all know, water is the most ideal fluid you can drink. Unfortunately, when you are...
By Nikki Martin, Director of Precision Medicine Initiatives, February 14, 2019
Nikki Martin, Director of Precision Medicine Initiatives at LUNGevity, had a virtual "sit-down" with Erica Schnettler, Medical Science Liaison at OneOme, to discuss pharmacogenomics testing. Erica has her BS in genetics and PhD in pharmacology and is passionate about using PGx to improve oncology patient health outcomes.
Nikki Martin: Let’s start with basic definition of pharmacogenomics.
Erica Schnettler: How your body responds to a drug is determined by many factors. Of those factors, your genes (or variations in your DNA that make you unique) can have...
By Upal Basu Roy, MPH, PhD, LUNGevity Senior Director of Research , February 13, 2019
Since the discovery of the first epidermal growth factor receptor (EGFR) mutation in lung cancer in 2004, targeted therapies and immunotherapies have become a major component of the treatment arsenal for non-small cell lung cancer (NSCLC). Biomarkers are features of a cancer that predict how it will respond to certain treatments. They help doctors select the most appropriate treatment for the cancer.
Two examples of biomarkers are:
Mutations within the cancer DNA (EGFR, ALK, ROS1, RET, etc.)
High levels of certain proteins (e.g., PD-L1 used to decide immunotherapy)